BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics (TNGX)Tango Therapeutics2026-06-25 13:46 ESTClinical readout

Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit Vopimetostat combinations with Revolution Medicines’ RAS(ON)

Open original release

Related news

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Appoints Sung Lee to Board of Directors

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

TNGXTango Therapeutics2026-06-25 13:46 EST

Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences

View all latest news

Tango Therapeutics

Tango Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TNGXTango Therapeutics2026-06-26 05:19 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-26 05:19 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-26 05:19 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

TNGXTango Therapeutics2026-06-26 05:19 EST

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

TNGXTango Therapeutics2026-06-26 05:19 EST

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States